QCM
FULC icon

Quantinno Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Quantinno Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Sell
25,669
-3,595
-12% -$33.3K ﹤0.01% 3202
2025
Q4 		$331K Buy
29,264
+4,615
+19% +$47K ﹤0.01% 2760
2025
Q3 		$227K Buy
+24,649
New +$178K ﹤0.01% 2677

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Quantinno Capital Management's FULC Position: Q1 2026 in Review

Quantinno Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 12% in Q1 2026, selling an estimated $33.3K and leaving 25,669 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #3202.

Quantinno Capital Management first reported a position in FULC in Q3 2025 and has held it in 3 quarters since. The position peaked at $331K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Quantinno Capital Management held 25,669 shares of Fulcrum Therapeutics worth $197K as of Q1 2026.
  • Quantinno Capital Management sold 3,595 Fulcrum Therapeutics shares in Q1 2026, an estimated $33.3K.
  • Fulcrum Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #3202 holding.
  • Quantinno Capital Management first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quantinno Capital Management's Fulcrum Therapeutics position peaked at $331K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.